

Second Regular Session
Seventy-fifth General Assembly
STATE OF COLORADO

ENGROSSED

*This Version Includes All Amendments Adopted
on Second Reading in the House of Introduction*

LLS NO. 26-0027.01 Shelby Ross x4510

SENATE BILL 26-006

SENATE SPONSORSHIP

Amabile and Kirkmeyer,

HOUSE SPONSORSHIP

Brown and Taggart,

Senate Committees

Health & Human Services
Appropriations

House Committees

A BILL FOR AN ACT

101 **CONCERNING PARITY FOR THE USE OF NON-OPIOID PAIN MANAGEMENT**
102 **DRUGS.**

Bill Summary

(Note: This summary applies to this bill as introduced and does not reflect any amendments that may be subsequently adopted. If this bill passes third reading in the house of introduction, a bill summary that applies to the reengrossed version of this bill will be available at <http://leg.colorado.gov>.)

The bill requires a health insurance carrier that provides prescription drug benefits to require that:

- The utilization review requirements, including prior authorization and step therapy, for a non-opioid drug prescribed and approved by the federal food and drug administration (FDA) for the treatment or management of

Shading denotes HOUSE amendment. Double underlining denotes SENATE amendment.
Capital letters or bold & italic numbers indicate new material to be added to existing law.
Dashes through the words or numbers indicate deletions from existing law.

SENATE
Amended 2nd Reading
April 17, 2026

chronic or acute pain (non-opioid pain management drug) are no more restrictive than the least restrictive utilization review requirements for opioid drugs prescribed for the treatment or management of chronic or acute pain;

- There is at least one clinically appropriate non-opioid prescription drug available as an alternative for each opioid prescription drug; and
- The cost-sharing, copayment, or deductible for a non-opioid pain management drug is not greater than the cost-sharing, copayment, or deductible for an opioid drug prescribed for the treatment or management of chronic or acute pain.

The bill requires the department of health care policy and financing to ensure that the utilization review requirements, including prior authorization or step therapy, for a non-opioid prescription drug prescribed and approved by the FDA for the treatment or management of chronic or acute pain are no more restrictive than the least restrictive utilization requirements for opioid drugs prescribed for the treatment or management of chronic or acute pain.

1 *Be it enacted by the General Assembly of the State of Colorado:*

2 **SECTION 1.** In Colorado Revised Statutes, 10-16-145.5, **add**
3 (2.5) as follows:

4 **10-16-145.5. Step therapy - prior authorization - prohibited -**
5 **stage four advanced metastatic cancer - non-opioid pain management**
6 **drug - definitions.**

7 (2.5) (a) NOTWITHSTANDING SECTION 10-16-145, A CARRIER THAT
8 PROVIDES PRESCRIPTION DRUG BENEFITS SHALL REQUIRE THAT:

9 (I) THE UTILIZATION REVIEW REQUIREMENTS, INCLUDING PRIOR
10 AUTHORIZATION AND STEP THERAPY, FOR A NON-OPIOID DRUG PRESCRIBED
11 AND APPROVED BY THE FDA FOR THE TREATMENT OR MANAGEMENT OF
12 CHRONIC OR ACUTE PAIN ARE NO MORE RESTRICTIVE THAN THE LEAST
13 RESTRICTIVE UTILIZATION REVIEW REQUIREMENTS FOR OPIOID DRUGS
14 PRESCRIBED FOR THE TREATMENT OR MANAGEMENT OF CHRONIC OR

1 ACUTE PAIN;

2 (II) THERE IS AT LEAST ONE NON-OPIOID PRESCRIPTION DRUG
3 AVAILABLE AS A CLINICALLY APPROPRIATE ALTERNATIVE FOR AN OPIOID
4 PRESCRIPTION DRUG; AND

5 (III) THE COST-SHARING, COPAYMENT, OR DEDUCTIBLE FOR A
6 NON-OPIOID DRUG PRESCRIBED FOR THE TREATMENT OR MANAGEMENT OF
7 CHRONIC OR ACUTE PAIN IS NO GREATER THAN THE COST-SHARING,
8 COPAYMENT, OR DEDUCTIBLE FOR AN OPIOID DRUG PRESCRIBED FOR THE
9 TREATMENT OR MANAGEMENT OF CHRONIC OR ACUTE PAIN.

10 (b) THIS SUBSECTION (2.5) DOES NOT APPLY TO A GROUP BENEFIT
11 PLAN ISSUED PURSUANT TO THE "STATE EMPLOYEE GROUP BENEFITS
12 ACT", PART 6 OF ARTICLE 50 OF TITLE 24.

13 == ==

14 **SECTION 2. Act subject to petition - effective date.** This act
15 takes effect at 12:01 a.m. on the day following the expiration of the
16 ninety-day period after final adjournment of the general assembly (August
17 12, 2026, if adjournment sine die is on May 13, 2026); except that, if a
18 referendum petition is filed pursuant to section 1 (3) of article V of the
19 state constitution against this act or an item, section, or part of this act
20 within such period, then the act, item, section, or part will not take effect
21 unless approved by the people at the general election to be held in
22 November 2026 and, in such case, will take effect on the date of the
23 official declaration of the vote thereon by the governor.